tbuckley/cabot-search huggingface dataset:
MEDU-33. HUMAN CEREBELLAR ORGANOIDS AS A NEW 3D MODEL OF MEDULLOBLASTOMA
Authors: Marica Anderle, Claudio Ballabio, Chiara Lago, Giuseppe Aiello, Luca Tiberi
Journal: Neuro-Oncology (2019)

Three-dimensional (3D) cell culture systems have gained increasing interest in drug discovery and tissue engineering due to their evident advantages in providing more relevant information and more predictive data for in vivo tests. Willing to increase the knowledge about Medulloblastoma Brain tumor we are developing Human cerebellar organoids derived from human iPSC: three-dimensional cultures that include multiple stem cell types, cell organization and features of human cerebellum. Notably, Medulloblastoma is the most common brain tumor affecting infants and stands as a cause for a high percentage of morbidity and mortality among cancer patients. To identify new Medulloblastoma driver genes we set up an innovative way to modify human cerebellar organoid, developing the first in-vitro 3D model of Medulloblastoma. We are mimicking human pathological conditions modifying this organoids with different putative oncogenes. Notably thanks to this type of model, we are able to study the functions of new Medulloblastoma driver genes in modulating stem cells differentiation and commitment in a three-dimensional structure, during the development of the organoid and the tumor. We speculate that our new Medulloblastoma 3D culture systems hold great promise for applications in infant tumor research, cancer cell biology and drug discovery, being the first human 3D in-vitro model that resembles human pathological conditions.
Bone Marrow Adiposity: Basic and Clinical Implications
Authors: Zachary L Sebo, Elizabeth Rendina-Ruedy, Gene P Ables, Dieter M Lindskog, Matthew S Rodeheffer, Pouneh K Fazeli, Mark C Horowitz
Journal: Endocrine Reviews (2019)

Abstract The presence of adipocytes in mammalian bone marrow (BM) has been recognized histologically for decades, yet, until recently, these cells have received little attention from the research community. Advancements in mouse transgenics and imaging methods, particularly in the last 10 years, have permitted more detailed examinations of marrow adipocytes than ever before and yielded data that show these cells are critical regulators of the BM microenvironment and whole-body metabolism. Indeed, marrow adipocytes are anatomically and functionally separate from brown, beige, and classic white adipocytes. Thus, areas of BM space populated by adipocytes can be considered distinct fat depots and are collectively referred to as marrow adipose tissue (MAT) in this review. In the proceeding text, we focus on the developmental origin and physiologic functions of MAT. We also discuss the signals that cause the accumulation and loss of marrow adipocytes and the ability of these cells to regulate other cell lineages in the BM. Last, we consider roles for MAT in human physiology and disease.
Cross-Sectional, Prospective, Evaluation of the Utility of Multi-Parametric MRI Imaging in Predicting Clinically Meaningful Outcomes in Autoimmune Hepatitis.
Authors: K Arndtz, J Hodson, P Eddowes, M Kelly, A Dennis, M Fiore, R Banerjee, S Neubauer, G Hirschfield
Journal: Hepatology (2018)
Engineering Regenerative Thymic Tissues to Restore Long-Term T Cell Lymphopoiesis
Authors: Hui Gai, Rafa Gras~Pena, Yogendra Verma, Vincent Fateh, Kazuya Ikeda, Beruh Dejene, Dullei Min, Jing Wang, Tomek Swigut, Ken I. Weinberg, Georg A. Hollander, Sarah Heilshorn, Maria-Grazia Roncarolo, Vittorio Sebastiano, Katja G. Weinacht
Journal: Blood (2018)
I 型干扰素与抗 MDA5 皮肌炎
Authors: S.H. Zhang, Y. Zhao, Q.B. Xie, Y. Jiang, Y.K. Wu, B. Yan
Journal: British Journal of Dermatology (2019)

皮肌炎 (DM) 是一种导致皮肤和肌肉炎症的罕见疾病。DM 有不同亚型,根据遗传学差异来具体定义。一种 DM 亚型(抗‐MDA5 DM )以称为抗‐黑色素瘤分化‐相关基因 5 的基因为特征,这一亚型与极高的间质性肺病 (ILD) 风险有关。在亚洲,10‐48% 的 DM 患者患有此型 DM。这项来自中国的研究旨在探索某些统称为 1 型干扰素系统的蛋白在这一类型 DM 发生中的角色。研究了抗‐MDA5 DM 患者,并与其他 DM 变种患者进行了比较。检测了血液(炎症细胞因子、B 细胞活化因子或‘BAFF’、涎液化糖链抗原‐6)和皮损(STAT1、ISG15 和 MxA)中的特定蛋白水平。抗‐MDA5 DM 患者中 IFN‐α 的血浆蛋白水平远高于其他 DM 亚型患者。来自抗‐MDA5 DM 患者中的皮肤活检以 STAT1、ISG15 和 MxA 蛋白的强表达(存在)为特征。在 IFN‐α 生成高的抗‐MDA5 DM/ILD 患者中,IFN‐α 和 BAFF 水平之间存在关联。此外,BAFF 水平增高与 KL‐ 6 浓度增高平行。这项研究确认了抗‐MDA5 DM 中 I 型 IFN 蛋白系统的活化异常。与 BAFF 相关的 IFN‐α 的过多生成可能与 ILD 发生有关。
A multiyear cross‐sectional study of U.S. national prescribing patterns of first‐generation sedating antihistamines in older adults with skin disease
Authors: I. Cenzer, N. Nkansah‐Mahaney, M. Wehner, M.M. Chren, T. Berger, K. Covinsky, K. Berger, K. Abuabara, E. Linos
Journal: British Journal of Dermatology (2019)

First‐generation antihistamines (FGAs) are classified as 'potentially inappropriate' for use in older patients (patients aged ≥ 65 years). However, the prevalence of and factors associated with FGA prescription have not been studied. To examine FGA prescription rates for older patients who visited dermatology offices, and compare them to those for younger patients (patients aged 18–65 years) who visited dermatology offices and those for older patients who visited primary‐care physicians (PCPs). This was a multiyear cross‐sectional observational study using data from the U.S. National Ambulatory Medical Care Survey (2006–2015). Visits by patients aged 18 years or older were included in the study; the data comprised 15 243 dermatology office visits and 66 036 PCP office visits. The main outcome was FGA prescription. Other variables included physician specialty (dermatologist or PCP), patient's age, diagnosis of dermatological conditions and reason for visit. For dermatology visits, the overall FGA prescription rate for older patients was similar to that for younger patients (1·5% vs. 1·2%; P = 0·19), even when the diagnosis was dermatitis or pruritus (3·7% vs. 4·8%; P = 0·21) or when itch was a complaint (7·6% vs. 6·7%; P = 0·64). However, the rate of FGA prescription for dermatology visits was lower than that for PCP visits, in analyses matched for patient and visit characteristics (3·9% vs. 7·4%; P = 0·02). Our findings suggest that FGAs are overprescribed to older patients but that dermatologists are less likely to prescribe FGAs than PCPs. What's already known about this topic? First‐generation antihistamines (FGAs) have been shown to pose substantial risks to older adults, including cognitive impairment, falls, confusion, dry mouth and constipation. Therefore, FGAs have been classified as 'potentially inappropriate' for use in older patients by the American Geriatrics Society. It has also been shown that dermatologists do not always take patient characteristics (e.g. age or life expectancy) into account when deciding on a treatment, instead following a 'one‐size‐fits‐all' approach. What does this study add? FGAs are often prescribed during dermatology visits, and prescription rates do not differ between older and younger patients. There were no significant differences in prescription rates when comparing younger and older adults with the same diagnosis or symptom (e.g. dermatitis, pruritus or itch). FGAs are prescribed at higher rates in primary‐care offices than in dermatology offices.
HGG-04. USE OF AN ADVANCED RNA-SEQ FUSION PIPELINE RESULTS IN THE TARGETED TREATMENT AND SUSTAINED CLINICAL RESPONSE OF CHILDREN WITH RECURRENT PEDIATRIC HIGH-GRADE GLIOMA
Authors: Kallen Schwark, Amy Bruzek, Chandan Kumar-Sinha, Sylvia Escolero, Bernard Marini, Amy Pasternak, Marcia Leonard, Patricia Robertson, Rajen Mody, Arul Chinnaiyan, Carl Koschmann
Journal: Neuro-Oncology (2019)

BACKGROUND: Pediatric diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG) have an average progression-free survival (PFS) of 3 months. Gene fusions in cancer are being targeted with promising results. However, targeting fusions in DIPG and HGG has largely been unexplored – in part due to lack of clinical RNA-seq and/or low sensitivity in fusion calling. METHODS: We performed DNA sequencing (1700 genes) and RNA-seq analysis with the MI-ONCOSEQ CODAC fusion pipeline designed for improved fusion detection regardless of breakpoint within gene body. We identified three targetable gene fusions in patients with DIPG or recurrent HGG and retrospectively compared treatment and outcome to 19 patients with HGG and DIPG targeted with non-fusion DNA alterations. RESULTS: The first patient is an 11-year-old with anaplastic oligodendroglioma carrying a novel FGFR3-PHGDH fusion. The patient was treated with the FGFR inhibitor ponatinib, resulting in 24 months PFS. The second patient is a 15-year-old with a thrice recurrent mixed glioneuronal tumor despite multiple tumor resections and radiation; their tumor was found to carry a ROS1-GOPC fusion. The patient was treated with the ROS1 inhibitor entrectinib and remains progression-free after 44 months. The third patient is a 5-year-old with DIPG carrying a novel CTTNBP2-MET fusion who was treated with the MET inhibitor cabozantinib but passed away after 9 months from diagnosis (of note, tumor carried 15 other gene fusions). Our patients with HGG and targeted fusions had more favorable clinical response in comparison to our targeted non-fusion patients (12 months PFS) and historical controls (3 months PFS). CONCLUSIONS: RNA-seq analysis with advanced fusion calling can result in the identification of promising treatment regimens for DIPG and HGG. We also show that patients with targeted fusions have potential for superior clinical response in comparison to therapies targeting other alterations.
Author Correction: Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia
Authors: Andrea Cortese, Roberto Simone, Roisin Sullivan, Jana Vandrovcova, Huma Tariq, Wai Yan Yau, Jack Humphrey, Zane Jaunmuktane, Prasanth Sivakumar, James Polke, Muhammad Ilyas, Eloise Tribollet, Pedro J. Tomaselli, Grazia Devigili, Ilaria Callegari, Maurizio Versino, Vincenzo Salpietro, Stephanie Efthymiou, Diego Kaski, Nick W. Wood, Nadja S. Andrade, Elena Buglo, Adriana Rebelo, Alexander M. Rossor, Adolfo Bronstein, Pietro Fratta, Wilson J. Marques, Stephan Züchner, Mary M. Reilly, Henry Houlden
Journal: Nature Genetics (2019)
Abstract 15058: Utility of the 0-Hour/1-Hour High-Sensitivity Cardiac Troponin T Algorithm in Asian Patients With Suspected Non-ST Elevation Myocardial Infarction
Authors: Masayuki Shiozaki, Kenji Inoue, Satoru Suwa, Chien-Chang Lee, Yuki Kimura, Kentaro Fukuda, Hiroshi Tamura, Masataka Sumiyoshi, Hiroyuki Daida
Journal: Circulation (2017)

Introduction: A rapid rule-out or rule-in protocol based on the 0-hour/1-hour algorithm using high-sensitivity cardiac troponin T (hs-cTnT) is recommended by the European Society of Cardiology (ESC...
Occupational exposure to solvents and lung function decline: A population based study
Authors: Sheikh M Alif, Shyamali Dharmage, Geza Benke, Martine Dennekamp, John Burgess, Jennifer L Perret, Caroline Lodge, Stephen Morrison, David Peter Johns, Graham Giles, Lyle Gurrin, Paul S Thomas, John Llewelyn Hopper, Richard Wood-Baker, Bruce Thompson, Iain Feather, Roel Vermeulen, Hans Kromhout, Debbie Jarvis, Judith Garcia Aymerich, E Haydn Walters, Michael J Abramson, Melanie Claire Matheson
Journal: Thorax (2019)

While cross-sectional studies have shown associations between certain occupational exposures and lower levels of lung function, there was little evidence from population-based studies with repeated lung function measurements.We aimed to investigate the associations between occupational exposures and longitudinal lung function decline in the population-based Tasmanian Longitudinal Health Study.Lung function decline between ages 45 years and 50 years was assessed using data from 767 participants. Using lifetime work history calendars completed at age 45 years, exposures were assigned according to the ALOHA plus Job Exposure Matrix. Occupational exposures were defined as ever exposed and cumulative exposure -unit- years. We investigated effect modification by sex, smoking and asthma status.Compared with those without exposure, ever exposures to aromatic solvents and metals were associated with a greater decline in FEV1 (aromatic solvents 15.5 mL/year (95% CI -24.8 to 6.3); metals 11.3 mL/year (95% CI -21.9 to - 0.7)) and FVC (aromatic solvents 14.1 mL/year 95% CI -28.8 to - 0.7; metals 17.5 mL/year (95% CI -34.3 to - 0.8)). Cumulative exposure (unit years) to aromatic solvents was also associated with greater decline in FEV1 and FVC. Women had lower cumulative exposure years to aromatic solvents than men (mean (SD) 9.6 (15.5) vs 16.6 (14.6)), but greater lung function decline than men. We also found association between ever exposures to gases/fumes or mineral dust and greater decline in lung function.Exposures to aromatic solvents and metals were associated with greater lung function decline. The effect of aromatic solvents was strongest in women. Preventive strategies should be implemented to reduce these exposures in the workplace.
Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity
Authors: Julia Bitzegeio, Shannon Majowicz, Dorothea Matysiak-Klose, Daniel Sagebiel, Dirk Werber
Journal: Eurosurveillance (2019)

BackgroundMeasles elimination is based on 95% coverage with two doses of a measles-containing vaccine (MCV2), high vaccine effectiveness (VE) and life-long vaccine-induced immunity. Longitudinal analysis of antibody titres suggests existence of waning immunity, but the relevance at the population-level is unknown.AimWe sought to assess presence of waning immunity by estimating MCV2 VE in different age groups (2-5, 6-15, 16-23, 24-30 and 31-42 years) in Berlin.MethodsWe conducted a systematic literature review on vaccination coverage and applied the screening-method using data from a large measles outbreak (2014/15) in Berlin. Uncertainty in input variables was incorporated by Monte Carlo simulation. In a scenario analysis, we estimated the proportion vaccinated with MCV2 in those 31-42 years using VE of the youngest age group, where natural immunity was deemed negligible.ResultsOf 773 measles cases (median age: 20 years), 40 had received MCV2. Average vaccine coverage per age group varied (32%-88%). Estimated median VE was > 99% (95% credible interval (CrI): 98.6-100) in the three youngest age groups, but lower (90.9%, 95% CrI: 74.1-97.6) in the oldest age group. In the scenario analysis, the estimated proportion vaccinated was 98.8% (95% CrI: 96.5-99.8).ConclusionVE for MCV2 was generally high, but lower in those aged 31-42 years old. The estimated proportion with MCV2 should have led to sufficient herd immunity in those aged 31-42 years old. Thus, lower VE cannot be fully explained by natural immunity, suggesting presence of waning immunity.
Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis
Authors: Jieni Xu, Jingjing Sun, Pui Yan Ho, Zhangyi Luo, Weina Ma, Wenchen Zhao, Sanjay B. Rathod, Christian A. Fernandez, Raman Venkataramanan, Wen Xie, Ai-Ming Yu, Song Li
Journal: Biomaterials (2019)
IMMU-22. SINGLE-CELL CHARACTERIZATION OF INTRATUMORAL AND SYSTEMIC IMMUNE POPULATIONS IN PEDIATRIC AND ADULT BRAIN TUMORS REVEALS DIFFERENCES IN SUBPOPULATION COMPOSITION, ACTIVATION AND MEMORY
Authors: Aaron Mochizuki, Alexander Lee, Alejandro Garcia, Robert Prins, Anthony Wang, Tom Davidson
Journal: Neuro-Oncology (2019)

INTRODUCTION: Mass cytometry is a recent technological advance that enables single-cell analysis of the tumor microenvironment, permitting the capture of up to 50 different markers per cell. Tumors of the central nervous system (CNS) in pediatric patients are known to be biologically different from similarly classified adult tumors. Single-cell omics can provide improved understanding of the immune environment in pediatric brain cancers and potentially differentiate them from homonymous adult tumors. METHODS: Using time-of-flight mass cytometry, we compared paired peripheral blood mononuclear cells (PBMCs) and tumor infiltrating CD45+ cells from pediatric patients with medulloblastoma (n = 1), metastatic Ewing sarcoma (n = 1), pediatric high grade glioma (n = 3) and atypical teratoid/rhabdoid tumors (n = 1) to paired PBMCs and tumor samples from 10 adult patients with newly diagnosed glioblastoma. RESULTS: Utilizing multidimensional scaling, we found that samples clustered together based on tumor type. Adult glioblastoma and pediatric high-grade gliomas demonstrated similar proportions of immune populations; medulloblastoma and metastatic Ewing sarcoma had higher proportions of CD4+ and CD8+ T cells compared to adult glioblastoma (adjusted P values < 0.05, general linear hypothesis test). The overall expression of CD27 and CD69 was higher in PBMCs from pediatric patients with high-grade glioma (adjusted P = 0.002 and 0.004, respectively, general linear hypothesis test). CONCLUSIONS: Immune cell populations in pediatric CNS tumors demonstrate distinct compositions in different diseases. Both pediatric high-grade gliomas and adult glioblastomas had similar immune populations with lower proportions of intratumoral T cells than other tumor types, suggesting a more suppressive milieu. However, pediatric high-grade gliomas exhibited increased markers of activation and memory in the periphery compared to their adult counterparts, indicating a more robust systemic immune response. Further exploration using single cell analyses could lead to improved understanding of the tumor microenvironment and targetable mechanisms in pediatric CNS tumors.
MEDU-12. TREATMENT RESULTS OF CHILDREN WITH METASTATIC MEDULLOBLASTOMA ACCORDING TO C-MYC/N-MYC/Iso17q AND MGMT TUMOR STATUS
Authors: Andrey Levashov, Dmitry Khochenkov, Anna Stroganova, Marina Ryzhova, Sergey Gorelyshev, Stepan Babelyan, Natalya Subbotina, Vadmante Daylidite, Svetlana Zagidullina, Igor Dolgopolov, Georgy Seregin, Dmitry Sidelnikov, Georgy Mentkevich
Journal: Neuro-Oncology (2019)

From 2008 to 2018 forty nine patients with de novo metastatic medulloblastoma were included in trials. Median age is 7.8 years (range, 4 – 17). Children underwent adjuvant therapy arm A (like-SJMB03, n = 14) from 2008 to 2014: craniospinal radiation (CSI) 36Gy + local radiation to the tumor bed – up to 54Gy (daily fraction 1.8Gy), 4 cycles (vincristine/HD-cyclophosphamide/cisplatin) with auto stem cell rescue; arm B (n = 19) from 2014 to 2018 – induction chemotherapy (vincristine/HD-cyclophosphamide/cisplatin/etoposide +/- HD-methotrexate), CSI 24.4 (without C-MYC/N-MYC/Iso17q), other 36Gy + local - up to 54Gy, 2 cycles thiophosphamide/carboplatin +/- 5-azacitidine, with auto stem cell transplantation; arm C (n = 16) – individual treatment program (including CSI 23.4-36Gy and HD-chemotherapy). R1 status was revealed in 24 patients (49%), M2/3 in 41 (83.7%), large-cell anaplastic histological variant in 8 (16.3%), MGMT protein expression in 23 (69.7%), iso17q in 20 (48.8%), N-MYC amplification in 5 (13.5%), C-MYC amplification in 2 (4.3%). Disease-free survival (DFS) was 38.5 ± 13.5% in arm A, 65.6 ± 19.9% in B, 28.6 ± 13.8% in C (p = 0.008), a median follow-up 54.7 ± 10.2 months (A), 24.3 ± 4.2 (B), 11.9 ± 3.4 (C). DFS was 16.7 ± 14.6% in group with MGMT-positive tumor; 23.2 ± 13.8% - with iso17q-positive tumor; 33.3 ± 25.5% - with C-MYC/N-MYC-positive tumor; with CSI 23.4 Gy 73.3 ± 11.4% (a median follow-up 24.5 ± 6.4 months), 90.9 ± 8.7% (arm B, a median follow-up 28.3 ± 6.2 months), with CSI 36 Gy 29.8 ± 10.8% (a median follow-up 32.7 ± 5.7 months), p = 0.320. 9 events were revealed in arm A, 6 in B, 11 in C (p = 0.055), relapses in 12 cases, progression in 7. Treatment related mortality was 16.3% (8 children, 5 - due to septic complications, 3 – other toxicity). Chemotherapy intensification could help us to reduce CSI dose down to 23.4 Gy in some patients with metastatic disease and C-MYC/N-MYC/Iso17q - negative tumor.
IMMU-13. CRISPR/CAS9-MEDIATED SILENCING OF SHP-1 SIGNIFICANTLY ENHANCES THE ANTI-GLIOMA ACTIVITY OF IL-13Rα2 CAR T CELLS
Authors: Christopher Petersen, Matthew Bell, Haley Houke, Zongzhen Yi, Stephen Gottschalk, Giedre Krenciute
Journal: Neuro-Oncology (2019)

High grade gliomas (HGG) remain some of the most difficult to treat pediatric malignancies resulting in dismal outcomes. As even the best treatments currently available show poor efficacy and high toxicity, there is an urgent need to develop new treatment approaches. Immunotherapy with T cells expressing chimeric antigen receptors (CARs) specific for the glioma antigen IL-13Rα2 is an attractive approach with high potential for improving outcomes. We recently demonstrated that IL-13Rα2 CAR T cells had potent anti-tumor activity in preclinical glioma models. Genetic modification of these CAR T cells further enhanced this efficacy both in vitro and in vivo. However, despite these modifications, brain tumors eventually recurred. Mechanistic studies revealed that limited CAR T-cell function was the primary cause of therapeutic failure. The goal of this project is to enhance the effector function of IL-13Rα2-CARs through CRISPR/Cas9-mediated silencing of SHP-1, a potent negative T cell regulator. We generated IL-13Rα2.SHP-1 KO CAR T cells by electroporation of IL13Rα2-CARs with SHP-1 targeted Cas9-sgRNA complexes which resulted in highly efficient SHP-1 knockout. Importantly, this method did not affect CAR expression level, T-cell viability, or phenotype. IL-13Rα2.SHP-1 KO CAR T cells showed enhanced in vitro proliferation in response to T cell receptor stimulation and were as efficient as IL-13Rα2 CAR T cells in killing IL-13Rα2-positive gliomas in vitro. Treatment of intracranial and subcutaneous U373 glioma-bearing mice with IL-13Ra2.SHP-1-KO CAR T cells resulted in a significant delay in tumor growth and significant survival advantage when compared to mice receiving control IL-13Rα2 CAR T cells. In conclusion, we demonstrate that silencing negative T cell regulators can enhance the in vivo anti-tumor activity of IL-13Ra2 CAR T cells. This study highlights the potential for CRISPR-based gene editing as a powerful approach for improving the therapeutic efficacy of CAR T cells for HGG.
Abstract 15687: Myocardial Coronary Flow Reserve Predicts Adverse Clinical Outcomes Independently of Luminal Angiographic Score
Authors: Viviany R Taqueti, Rory Hachamovitch, Masanao Naya, Venkatesh L Murthy, Ron Blankstein, Sharmila Dorbala, Jon Hainer, Marcelo F Di Carli
Journal: Circulation (2013)

Background: Coronary vascular dysfunction, even in the absence of overt obstructive coronary artery disease (CAD), identifies patients at risk for cardiac death. We tested the hypothesis that prese...
Abstract 18730: Vitamin D and Cardiovascular Mortality: An Individual Participant Data Meta-Analysis With Standardized 25-Hydroxyvitamin D
Authors: Martin R Grubler, Martin Gaksch, Rolf Jorde, Winfried März, Vilmundur Gudnason, Jacqueline Dekker, Lars Rejnmark, Michael Thamm, Mairead Kiely, Kevin Cashman, Stefan Pilz
Journal: Circulation (2016)

Background: Vitamin-D deficiency (25(OH)D) is associated with an increased risk for cardiovascular (CV)-mortality. Nevertheless cut-off values remain debated and interventional studies reported lar...
Abstract 17193: Oral Anticoagulation in Addition to Dual Anti-platelet Therapy is Essential in Atrial Fibrillation Patients Experiencing Acute Myocardial Infarction With Percutaneous Coronary Intervention
Authors: Ki Hong Lee, Myung Ho Jeong, Hyung Wook Park, Dae Young Hyun, Jumin Won, Sung Sik Oh, Hyung Ki Jeong, Youngkeun Ahn, Jeong Gwan Cho
Journal: Circulation (2017)

Introduction: Oral anticoagulants (OACs) and dual anti-platelet therapy (DAPT) is needed to reduce thromboembolism and stent thrombosis in atrial fibrillation (AF) patients experiencing acute myoca...